Biomarkers for Lung Cancer Testing
March 21, 2014
Optimal Lung Cancer Treatment Requires Biomarker Testing
Biomarkers for lung cancer testing and biomarker testing are the subject of this important medical segment. Join Drs Gary Palmer and Deborah Morosini of Foundation Medicine as they share insight on the importance of testing and multidisciplinary coordination in its implementation and success. You’ll learn how this has had personal impact, and how the diagnosis and treatment of lung cancer is rapidly evolving. Learn how physicians are prolonging and improving the lives of cancer victims. Visit www.LetsTestNow.com or www.BoehringerIngelheim.com
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.